Recent updates indicate that GRAND PHARMA (00512), an innovative international pharmaceutical company listed in Hong Kong, has made further progress in nuclear medicine research and development. The global Phase I clinical trial (IPAX-2) for its innovative radio-drug conjugate (RDC) TLX101, targeting newly diagnosed primary glioblastoma (a form of brain cancer), has completed full patient enrollment. Notably, no dose-limiting toxicities (DLT) were observed, including at the maximum administered dose (two doses of 5GBq each, for a total radioactivity of 10GBq). Industry experts suggest that TLX101 has the potential to overcome the traditional treatment bottlenecks for glioblastoma, emerging as a pioneering innovative therapy in this field. This overseas clinical milestone strongly validates its clinical value and development potential. As GRAND PHARMA accelerates the global development pace of its innovative nuclear medicine products, the company is well-positioned to further solidify its leading role in this promising global market.
TLX101, a RDC drug developed by GRAND PHARMA for treating glioblastoma multiforme, is designed to freely cross the blood-brain barrier. It targets the L-type amino acid transporter 1 (LAT-1), which is overexpressed in glioblastoma cells, delivering precise radiation to induce cancer cell apoptosis. This dual-action "targeting + radiotherapy" mode allows for precise attacks on solid tumors while eliminating microscopic metastases that are difficult to reach with surgery or radiation. Furthermore, through its companion diagnostic agent TLX101-CDx and PET imaging technology, it enables accurate patient stratification prior to treatment. TLX101 has been granted Orphan Drug Designation by the U.S. FDA, marking it as a highly promising innovative treatment for glioma worldwide.
The IPAX-2 study is an international, multicenter, open-label Phase I dose-escalation trial. Its objective is to evaluate the safety and tolerability of TLX101 in combination with standard post-surgical therapy (external beam radiation and temozolomide) for newly diagnosed primary glioblastoma. The study, conducted across research centers in Australia, Austria, and the Netherlands, has completed enrollment of 12 patients and explored three dose-escalation cohorts. To date, the study has reached the maximum administered dose without observing any dose-limiting toxicities, demonstrating excellent safety and tolerability profiles. This provides a solid foundation for determining the maximum tolerated dose in subsequent pivotal clinical trials. Patients will continue to receive standard treatment until the study concludes, at which point the MTD will be confirmed as the primary endpoint.
Concurrently, the pivotal study for TLX101 in treating recurrent glioblastoma (IPAX BrIGHT) is actively enrolling and dosing patients in Australia and the Netherlands. It has also received approval in Austria and Belgium, with patient enrollment set to commence shortly. This development signifies that TLX101 is poised to become the first radiopharmaceutical therapy to enter Phase III development for glioblastoma, maintaining a leading position in global clinical development. Preliminary clinical benefits of TLX101 were previously validated in an overseas Phase II clinical trial (IPAX-Linz study). Clinical results indicated that recurrent glioblastoma patients treated with TLX101 achieved a median overall survival (OS) of approximately 11.9 months (about 32.2 months from initial diagnosis), which is significantly superior to traditional treatment regimens. The treatment also demonstrated a favorable overall safety profile with no serious adverse events, laying a robust foundation for subsequent clinical development and application.
Central nervous system tumors rank as the tenth leading cause of death globally, with brain tumors accounting for up to 90% of these cases. Glioblastoma, originating from astrocytes, constitutes 50.1% of all primary malignant central nervous system tumors. It is one of the most aggressive primary brain tumors, often referred to as the "king of cancers." Classified as Grade 4 by the World Health Organization (WHO), it represents the highest level of malignancy. In China, the annual incidence of glioma is approximately 6.4 per 100,000 people, with glioblastoma incidence ranging from 3 to 5 per 100,000. The median age at diagnosis is 65. This tumor is highly malignant with an extremely high recurrence rate. Even with standard treatment combining surgery, radiotherapy, and chemotherapy, the median survival for patients is only 12-15 months, with a 5-year survival rate of about 10%, highlighting a significant long-term unmet clinical need.
According to research data, the global glioblastoma treatment market reached approximately 7.522 billion yuan in 2023 and is projected to grow to around 13.968 billion yuan by 2029, representing a compound annual growth rate of about 8.8%. If the development of GRAND PHARMA's TLX101 proceeds smoothly, it could offer a novel treatment approach for glioblastoma and provide a new growth driver for the company.
The milestone achievement of TLX101 overseas not only represents a significant victory in its clinical development but also deeply reflects GRAND PHARMA's global strategy in the nuclear medicine oncology sector, encompassing comprehensive industry chain construction and an integrated diagnosis-and-treatment approach. In recent years, GRAND PHARMA has consistently focused on the nuclear medicine oncology field, establishing a full-chain industrial system covering R&D, production, distribution, and sales from a global perspective, positioning itself as a leader in the global nuclear medicine oncology sector.
Regarding global deployment, the company has established R&D centers with hubs in Boston and Chengdu, supported by production bases in Boston, Frankfurt, Singapore, and Chengdu. This is complemented by a commercialization network covering over 50 countries and regions, enabling the seamless progression of innovative nuclear medicines from initial R&D and scaled production to global promotion. Furthermore, the company's radioactive drug R&D and production base in Wenjiang, Chengdu, serves as the world's first closed-loop platform for the entire nuclear medicine industry chain. It achieves full-chain control over isotope preparation, nuclear drug R&D, clinical production, and commercialization, effectively overcoming key technological barriers in the nuclear medicine field. This provides a solid guarantee for the rapid industrialization of global innovative products and empowers the company with source innovation and global clinical development capabilities.
In terms of product pipeline strategy, the company firmly adheres to the core concept of "integrated diagnosis and treatment," building a multi-layered, high-quality portfolio of innovative nuclear medicines. Currently, the company has 16 innovative nuclear medicine products in the R&D and registration stages, involving five key radionuclides: 68Ga, 177Lu, 131I, 90Y, and 89Zr. These products comprehensively cover seven high-incidence cancer types, including liver cancer, prostate cancer, kidney cancer, and brain cancer, forming a well-rounded pipeline that synergizes diagnosis and treatment across multiple indications. To date, six of the company's innovative RDC drugs have entered registered clinical studies, with one in the NDA stage and three in Phase III clinical stages. This makes GRAND PHARMA the company with the largest pipeline of diagnostic and therapeutic RDC innovative drugs in Phase III clinical studies in China, while also possessing a rich product portfolio and integrated diagnosis-treatment layout advantages globally.
Leveraging its continuously strengthened full-industry-chain barriers and global innovation capabilities, GRAND PHARMA's nuclear medicine oncology segment maintains high-quality, rapid growth. The scaling of core products and the advancement of innovative pipelines form a virtuous cycle, with the revenue contribution from products with strong innovation barriers consistently increasing, serving as a core growth engine for the company's long-term development.
This recent overseas clinical breakthrough with TLX101 further deepens the company's therapeutic footprint in the brain cancer field and validates its "Go Global" development strategy. GRAND PHARMA stated that it will continue to adhere to its patient-centric innovation philosophy, persistently increase R&D investment in the global nuclear medicine sector, accelerate the clinical advancement and translation of major innovative products, and continuously enrich and perfect its nuclear medicine product pipeline and full-industry-chain layout. Through its strategic framework of global operations and dual-circulation development, the company aims to consistently reinforce its leadership position in the global nuclear medicine oncology field, contributing to conquering more malignant tumors, improving the quality of life for patients worldwide, and propelling China's nuclear medicine industry to the global forefront.
Comments